Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1996 2
1997 13
1998 38
1999 31
2000 47
2001 40
2002 87
2003 161
2004 197
2005 249
2006 290
2007 321
2008 381
2009 381
2010 426
2011 475
2012 499
2013 501
2014 506
2015 556
2016 481
2017 529
2018 589
2019 582
2020 638
2021 674
2022 58
Text availability
Article attribute
Article type
Publication date

Search Results

7,702 results
Results by year
Filters applied: . Clear all
Page 1
Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.
Maertens JA, Rahav G, Lee DG, Ponce-de-León A, Ramírez Sánchez IC, Klimko N, Sonet A, Haider S, Diego Vélez J, Raad I, Koh LP, Karthaus M, Zhou J, Ben-Ami R, Motyl MR, Han S, Grandhi A, Waskin H; study investigators. Maertens JA, et al. Lancet. 2021 Feb 6;397(10273):499-509. doi: 10.1016/S0140-6736(21)00219-1. Lancet. 2021. PMID: 33549194 Clinical Trial.
BACKGROUND: Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to ass …
BACKGROUND: Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet f …
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.
Maertens JA, Raad II, Marr KA, Patterson TF, Kontoyiannis DP, Cornely OA, Bow EJ, Rahav G, Neofytos D, Aoun M, Baddley JW, Giladi M, Heinz WJ, Herbrecht R, Hope W, Karthaus M, Lee DG, Lortholary O, Morrison VA, Oren I, Selleslag D, Shoham S, Thompson GR 3rd, Lee M, Maher RM, Schmitt-Hoffmann AH, Zeiher B, Ullmann AJ. Maertens JA, et al. Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10. Lancet. 2016. PMID: 26684607 Clinical Trial.
The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. METHODS: This was a phase 3, double-blind, global multicentre, comparative-group study. ...Drug-related adverse events were reported in 109 (42%) pat …
The SECURE trial assessed efficacy and safety of isavuconazole versus voriconazole in patients with invasive mould disease. METHODS: …
Adverse effects of voriconazole: Over a decade of use.
Levine MT, Chandrasekar PH. Levine MT, et al. Clin Transplant. 2016 Nov;30(11):1377-1386. doi: 10.1111/ctr.12834. Epub 2016 Oct 14. Clin Transplant. 2016. PMID: 27581783 Review.
Some toxicities (neuropsychiatric and gastrointestinal including hepatic) are seen in clear association with supratherapeutic serum voriconazole levels; thus, careful monitoring of voriconazole levels is a critical component of safe drug use. Guidelines for screenin …
Some toxicities (neuropsychiatric and gastrointestinal including hepatic) are seen in clear association with supratherapeutic serum voric
Utility of voriconazole therapeutic drug monitoring: a meta-analysis.
Luong ML, Al-Dabbagh M, Groll AH, Racil Z, Nannya Y, Mitsani D, Husain S. Luong ML, et al. J Antimicrob Chemother. 2016 Jul;71(7):1786-99. doi: 10.1093/jac/dkw099. Epub 2016 May 10. J Antimicrob Chemother. 2016. PMID: 27165788
BACKGROUND: Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of voriconazole TDM to guide therapy remains uncertain and controversial. ...
BACKGROUND: Voriconazole therapeutic drug monitoring (TDM) is increasingly used in clinical practice. However, the utility of vori
Evaluating a voriconazole dose modification guideline to optimize dosing in patients with hematologic malignancies.
Perreault S, McManus D, Anderson A, Lin T, Ruggero M, Topal JE. Perreault S, et al. J Oncol Pharm Pract. 2019 Sep;25(6):1305-1311. doi: 10.1177/1078155218786028. Epub 2018 Jul 12. J Oncol Pharm Pract. 2019. PMID: 29996736
METHODS: This prospective study included 128 patients with 250 admissions who received voriconazole from July 2014 to February 2016. Eligible adult patients receiving voriconazole for prophylaxis or treatment with at least one trough level, drawn appropriately, were …
METHODS: This prospective study included 128 patients with 250 admissions who received voriconazole from July 2014 to February 2016. …
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis.
Jin H, Wang T, Falcione BA, Olsen KM, Chen K, Tang H, Hui J, Zhai S. Jin H, et al. J Antimicrob Chemother. 2016 Jul;71(7):1772-85. doi: 10.1093/jac/dkw045. Epub 2016 Mar 10. J Antimicrob Chemother. 2016. PMID: 26968880 Free PMC article. Review.
OBJECTIVES: The optimum trough concentration of voriconazole for clinical response and safety is controversial. The objective of this review was to determine the optimum trough concentration of voriconazole and evaluate its relationship with efficacy and safety. ... …
OBJECTIVES: The optimum trough concentration of voriconazole for clinical response and safety is controversial. The objective of this …
Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
Yi WM, Schoeppler KE, Jaeger J, Mueller SW, MacLaren R, Fish DN, Kiser TH. Yi WM, et al. Ann Clin Microbiol Antimicrob. 2017 Sep 11;16(1):60. doi: 10.1186/s12941-017-0235-8. Ann Clin Microbiol Antimicrob. 2017. PMID: 28893246 Free PMC article.
METHODS: This study was a retrospective cohort study conducted at the University of Colorado Hospital between September 2006 and June 2015 that evaluated patients who received posaconazole or voriconazole TDM as part of routine care. RESULTS: Voriconazole (n = 250) …
METHODS: This study was a retrospective cohort study conducted at the University of Colorado Hospital between September 2006 and June 2015 t …
Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children.
Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicolò A, Cusato J, Di Perri G, D'Avolio A. Allegra S, et al. Br J Clin Pharmacol. 2018 Jan;84(1):197-203. doi: 10.1111/bcp.13401. Epub 2017 Sep 24. Br J Clin Pharmacol. 2018. PMID: 28805964 Free PMC article.
Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. Here, we aimed to describe our experience with voriconazole for treatment and prophylaxis of invasive fungal infections in paediatric
Voriconazole therapeutic drug monitoring is not consistently recommended due to its high interpatient and intrapatient variability. H
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.
Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ. Moriyama B, et al. Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18. Clin Pharmacol Ther. 2017. PMID: 27981572 Free PMC article.
Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant CYP2C19 alleles. ...We summarize evidence from the literature supporting this association and provide therapeutic recommendations for the u
Voriconazole, a triazole antifungal agent, demonstrates wide interpatient variability in serum concentrations, due in part to variant
Isavuconazole Is as Effective as and Better Tolerated Than Voriconazole for Antifungal Prophylaxis in Lung Transplant Recipients.
Samanta P, Clancy CJ, Marini RV, Rivosecchi RM, McCreary EK, Shields RK, Falcione BA, Viehman A, Sacha L, Kwak EJ, Silveira FP, Sanchez PG, Morrell M, Clarke L, Nguyen MH. Samanta P, et al. Clin Infect Dis. 2021 Aug 2;73(3):416-426. doi: 10.1093/cid/ciaa652. Clin Infect Dis. 2021. PMID: 32463873 Free PMC article.
We compared effectiveness and tolerability of isavuconazole and voriconazole prophylaxis in lung transplant recipients. METHODS: A single-center, retrospective study of patients who received isavuconazole (September 2015-February 2018) or voriconazole (September 201 …
We compared effectiveness and tolerability of isavuconazole and voriconazole prophylaxis in lung transplant recipients. METHODS: A si …
7,702 results